APA

Inal A., Kos F. T., Algin E., Yildiz R., Dikiltas M., Unek I. T., Colak D., Elkiran E. T., Helvaci K., Geredeli C., Dane F., Balakan O., Kaplan M. A., Durnali A. G., Harputoglu H., Goksel G., Ozdemir N., Buyukberber S., Gumus M., Kucukoner M., Ozkan M., Uncu D., Benekli M. & Isikdogan A. (20120717). Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study. : Neoplasma.

Chicago

Inal A, Kos F T, Algin E, Yildiz R, Dikiltas M, Unek I T, Colak D, Elkiran E T, Helvaci K, Geredeli C, Dane F, Balakan O, Kaplan M A, Durnali A G, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Gumus M, Kucukoner M, Ozkan M, Uncu D, Benekli M and Isikdogan A. 20120717. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study. : Neoplasma.

Harvard

Inal A., Kos F. T., Algin E., Yildiz R., Dikiltas M., Unek I. T., Colak D., Elkiran E. T., Helvaci K., Geredeli C., Dane F., Balakan O., Kaplan M. A., Durnali A. G., Harputoglu H., Goksel G., Ozdemir N., Buyukberber S., Gumus M., Kucukoner M., Ozkan M., Uncu D., Benekli M. and Isikdogan A. (20120717). Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study. : Neoplasma.

MLA

Inal A, Kos F T, Algin E, Yildiz R, Dikiltas M, Unek I T, Colak D, Elkiran E T, Helvaci K, Geredeli C, Dane F, Balakan O, Kaplan M A, Durnali A G, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Gumus M, Kucukoner M, Ozkan M, Uncu D, Benekli M and Isikdogan A. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study. : Neoplasma. 20120717.